JP Morgan Chase
BCYC

JP Morgan Chase’s Bicycle Therapeutics BCYC Stock Holding History

JP Morgan Chase’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.8K Sell
9,873
-8,482
-46% -$48.5K ﹤0.01% 6256
2025
Q4 		$130K Buy
18,355
+10,228
+126% +$75.4K ﹤0.01% 5755
2025
Q3 		$62.9K Buy
8,127
+490
+6% +$3.7K ﹤0.01% 6141
2025
Q2 		$53.1K Buy
7,637
+593
+8% +$4.72K ﹤0.01% 5905
2025
Q1 		$59.8K Sell
7,044
-663
-9% -$7.81K ﹤0.01% 5805
2024
Q4 		$108K Sell
7,707
-717
-9% -$15.4K ﹤0.01% 5728
2024
Q3 		$191K Buy
8,424
+1,782
+27% +$41.1K ﹤0.01% 5425
2024
Q2 		$134K Sell
6,642
-8,946
-57% -$202K ﹤0.01% 5370
2024
Q1 		$388K Buy
15,588
+5,482
+54% +$116K ﹤0.01% 4960
2023
Q4 		$183K Sell
10,106
-58,393
-85% -$966K ﹤0.01% 5433
2023
Q3 		$1.38M Sell
68,499
-27,652
-29% -$632K ﹤0.01% 3844
2023
Q2 		$2.45M Buy
96,151
+9,013
+10% +$209K ﹤0.01% 3386
2023
Q1 		$1.85M Buy
87,138
+3,932
+5% +$98.6K ﹤0.01% 3596
2022
Q4 		$2.46M Sell
83,206
-42,483
-34% -$1.14M ﹤0.01% 3404
2022
Q3 		$2.92M Buy
125,689
+42,231
+51% +$1M ﹤0.01% 3165
2022
Q2 		$1.4M Buy
83,458
+73,555
+743% +$1.55M ﹤0.01% 3837
2022
Q1 		$434K Buy
9,903
+7,075
+250% +$330K ﹤0.01% 4789
2021
Q4 		$172K Buy
2,828
+1,463
+107% +$80.7K ﹤0.01% 5433
2021
Q3 		$57K Sell
1,365
-691
-34% -$24.2K ﹤0.01% 5791
2021
Q2 		$63K Buy
2,056
+754
+58% +$22.8K ﹤0.01% 5672
2021
Q1 		$39K Buy
+1,302
New +$33.6K ﹤0.01% 5587

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase's BCYC Position: Q1 2026 in Review

JP Morgan Chase reduced its Bicycle Therapeutics (BCYC) stake by 46% in Q1 2026, selling an estimated $48.5K and leaving 9,873 shares worth $42.8K. The position accounts for ﹤0.01% of the portfolio, ranked #6256.

JP Morgan Chase first reported a position in BCYC in Q1 2021 and has held it in 21 quarters since. The position peaked at $2.92M in Q3 2022. 98 funds tracked by Wall St. Rank hold BCYC as of Q1 2026.

  • JP Morgan Chase held 9,873 shares of Bicycle Therapeutics worth $42.8K as of Q1 2026.
  • JP Morgan Chase sold 8,482 Bicycle Therapeutics shares in Q1 2026, an estimated $48.5K.
  • Bicycle Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6256 holding.
  • JP Morgan Chase first reported a position in Bicycle Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • JP Morgan Chase's Bicycle Therapeutics position peaked at $2.92M in Q3 2022.
  • 98 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.